09:01 AM EST, 12/09/2024 (MT Newswires) -- AbbVie ( ABBV ) said Monday that a phase 3 trial evaluating Tavapadon as a monotherapy to treat Parkinson's Disease met both its primary and secondary endpoints.

The company said the trial's primary endpoint involved demonstrating a statistically significant improvement from baseline in the Movement Disorder Society - Unified Parkinson's Disease Rating Scale Parts 2 and 3 combined score at week 26.

AbbVie ( ABBV ) said the trial also met a key secondary endpoint as it demonstrated a statistically significant and clinically meaningful improvement in motor aspects of experiences of daily living compared with placebo at week 26.

The biopharmaceutical company said it is on track to submit a New Drug Application to the US Food and Drug Administration in 2025.

Shares were edging 0.3% higher in recent premarket activity.